Purpose: The Ketogenic Diet (KD) is a well-established treatment for epilepsy in children and adults. We describe our 10-year KD experience in children less than two years of age diagnosed with medically refractory epilepsy. Methods: We conducted a retrospective case-note review of infants managed with KD at our centre between 2006 and 2016. Results: Twenty-nine children between 2 1 / 2 weeks and 23 months of age were identified, with mixed epilepsy aetiologies. Ninety-three percent had daily seizures and 82% were on two or more anti-epilepsy drugs (AEDs) at the time of KD commencement. KD was continued for more than four weeks in 86%. Based on a combination of parental reports, hospital observations and seizure diaries, two of 29 became seizure free, seven demonstrated >50% seizure reduction, and eight showed a decrease in seizure intensity/frequency. No adverse effects were observed in 45% patients, and dietary therapy was stopped in only two because of poor tolerability. Conclusion: We conclude that KD can be utilised and is generally well tolerated in infants with severe epilepsies. In addition, our experience suggests efficacy with improved seizure frequency/severity in around 50% without adverse effects on developmental outcome.
Introduction
The ketogenic Diet (KD) is a well-established therapy in the management of pharmaco-resistant epilepsy in children [1] . Neal et al demonstrated a significantly reduced seizure frequency in threemonth KD treatment compared with standard AED treatment in 2-16 year-old children with mixed epilepsy aetiologies [2] . Dietary therapy was well-tolerated with only mild side-effects in 25% patients. Others have reported benefits of dietary therapies in children selected according to epilepsy syndromic diagnosis [3] [4] [5] [6] . The KD is also reported to improve alertness, attention and cognition [7] .
The incidence of epilepsy is higher, and seizure control and developmental outcomes are worse during the first two years of life than in any other age of childhood [8] . Previous studies of dietary therapy in young children have reported benefit in infantile spasms [4, 9, 10] .
We describe our ten-year KD experience in infants (<2 yearsold) diagnosed with refractory epilepsy. Our aim was to assess the feasibility, tolerability and efficacy of dietary therapy in infants with intractable seizures.
Methods
Our retrospective case-note review included all infants (<2-year-old) diagnosed with a medication refractory epilepsy and started on the KD at the Evelina London Children's Hospital between 2006 and 2016.
Our KD protocol was developed following discussions with other leading KD experts in the UK and is largely consistent with the later published guidelines [11, 12] . We generally initiate KD at home without fasting or fluid restriction. Nutritional requirements were assessed for each patient before KD commencement. Most infants were provided with a classical 3:1 KD (fat:protein + carbohydrate ratio) with adjustments as necessary according to their clinical response and urine ketone monitoring. The MCT and modified diets are also used at our centre when the specialist dietitian judges them to be more appropriate following a detailed dietetic evaluation.
Prior to KD commencement our usual practice is to estimate a baseline seizure frequency from parental reports and seizure diaries (if parents use them), review drug histories, EEG findings, baseline laboratory tests and agree individual therapy goals for each patient. Impact of the KD on seizure control, general wellbeing and biochemical adverse events are evaluated at clinical reviews at 1, 3, 6, 12 and 18 months whilst children continue on the KD.
Using a structured proforma, we reviewed hospital medical and electronic patient records, neurophysiology results, dietitians' reports, seizure diaries (4/29), and laboratory blood analyses. Information was also collected on age at KD commencement; epilepsy syndromic diagnoses; seizure type, onset, and frequency; concomitant AEDs; place of starting KD; KD type, duration, sideeffects; and reasons for its discontinuation. KD efficacy was assessed based on a reduction of seizure frequency and/or number of AEDs at the end of treatment, change of seizure pattern, and use of rescue medications. Patients who did not show any improvement in seizure control were considered non-responders. Although we did not perform standardised assessments of developmental progress, we recorded parental reports on behaviour (level of alertness, developmental and play skills, mood, attention and communication).
The study was approved by the audit committee of the Evelina London Children's Hospital.
Results
Between 2006 and 2016, 32 infants were referred to our service for consideration of dietary therapy for epilepsy. Twenty-nine infants (18:11 = M:F) between 2 1 / 2 weeks and 23 months of age at KD commencement were eligible and included in this study.
All patients had pharmaco-resistant epilepsy with on-going frequent seizures of mixed aetiology, of which 27 (93%) had daily seizures. In 18, seizure onset was within the first month of life and 83% patients were on treatment with 2 AEDs at KD commencement. In 15 children (52%) symptomatic epilepsies were diagnosed and no underlying cause was identified in the remaining 14 (Table 1) .
Fifty percent patients started KD at <12 months old and 31% at <6 months old. Twenty-eight of 29 patients were established on a classical KD with 3:1 ratio in 19/28. One infant had MCT diet. All patients developed ketonuria. KD was established in a hospital setting in 65.5% (including 2 infants treated in an intensive care environment in PICU) in contrast to our usual practice in older children.
For the majority patients, the diet improved seizure control and/or developmental progress. Based on combination of parental reports, hospital observations and seizure diaries (in some), we noted a decrease in seizure frequency or intensity in 52% patients, of which 7/29 (2-HIE & Hypoglycaemic brain damage, 2-Dravet and Dravet-like syndromes, 1-Pyridoxal phosphate dependent seizures, 2-unknown-likely genetic causes) demonstrated >50% seizure reduction at 1-month and 3-month reviews, 3/29 (1-HIE, 1-Dynamin gene mutation and 1-unknown-likely genetic cause)-<50% seizure reduction at 3-month and 6-month reviews, and 5/ 29 (1-Tuberous Sclerosis, 1-Dravet syndrome, 3-unknown-likely genetic causes)-some decrease in seizure intensity at 1-month and 3-month reviews. There was no difference in the number of nonresponders to KD across aetiological diagnoses. In addition, in 2/29 continuous intravenous Midazolam infusion was successfully weaned off in PICU following KD commencement.
We identified a shift towards reduction in the number and even discontinuation of AEDs prescribed after the diet initiation ( Table 2) . We also noted a tendency for a better response to KD commenced at <12 months old (28%) compared to >12 months old (21%).
Of 24 patients maintained on KD for >4 weeks, 10 continued treatment for >6 months. This reflects our local practice with a pragmatic approach to continuing KD only when initial goals are at least partially achieved and KD benefits outweigh harm. The diet was discontinued in only 2/29 (7%) infants because of poor tolerability and in 8/29 (28%) because of lack of benefit. Out of 29 patients, 9 died during or after KD therapy from the underlying disease and severe co-morbidities including cardio-respiratory conditions.
All patients had clinical and biochemical monitoring of their progress at outpatient reviews 1, 3, 6, 12 and 18 months after starting dietary therapy. Seventy-five percent patients experienced no side-effects or had only mild vomiting or constipation. Adverse biochemical events (for example: hypervitaminosis E, hypercholesterolaemia, or zinc level disturbances) were found in 38% patients, but in no case was of sufficient severity alone to discontinue KD.
We also noted a beneficial KD effect on patients' alertness and developmental status within the three months of starting diet. Thus, in 18/29 (62%) parents and carers reported improved alertness, of whom 9/18 also made some developmental gains (mainly in motor skills). Six showed improved sleep and five had improved mood and behaviour. In some cases, parents wanted to continue KD due to the perceived beneficial cognitive effects despite non-significant seizure reduction.
Discussion
We have confirmed that the KD can be used to benefit infants with drug refractory epilepsy without significant harm. Kossoff et al described KD safety and showed efficacy as >50% improvement in infantile spasms after 6-month treatment [4, 13] . Our findings are comparable to those previously reported by Nordli et al as their study was not limited to epilepsy syndrome or seizure type [10] . In contrast to our practice, all their patients were hospitalised for 24-48 hour fasting before initiating KD, aiming to establish ketonuria rapidly. Similar to our findings, more recent studies on the KD treatment demonstrated an overall good seizure control (61%) and seizure freedom (27%, significantly higher rate with early KD initiation) in infants with refractory epilepsy [14] without prior fasting or fluid restriction. However, dietary therapy was initiated only in hospital settings. Dressler et al included children of all ages although they grouped infants (<1 1 / 2 -year old) separately and compared them with older children [14] .
Comparison of KD efficacy among groups of different aetiological diagnoses was limited due to uneven sample size in each group. However, our results suggest a possible superior response to KD therapy in patients with non-structural causes of epilepsy.
We also saw a beneficial effect on behavioural and/or developmental improvement within three months of KD commencement. Health related quality of life may therefore improve, although this is not easily measured. Nordli et al report similar results within six months [10] . Zhu et al showed an improvement of neurobehavioural development on KD treatment in 14 of 24 patients [7] . However, in our study it was not possible to determine whether a cognitive improvement was directly attributable to KD or associated with a reduction of AEDs, better seizure control, or to the natural history of the underlying condition or to some combination of these.
The strengths of our study are the relatively large cohort of infants with refractory epilepsy, long follow-up observation and detailed clinical data. Limitations include that we were unable to perform detailed cognitive/developmental testing, and that most parents/carers didnot complete detailed seizure diaries. We were unable to evaluate the relative contribution of dietary therapy and/ or medication reduction on the perceived developmental improvements seen by parents/carers.
In conclusion, the KD can be effectively utilised and is generally well-tolerated in infants with refractory epilepsy and should be considered as a therapeutic option for this severely affected group. We have demonstrated that in >50% infants there is a reported net benefit in terms of seizure burden, a reduction in prescribed AEDs, improvements in mood and alertness and sometimes developmental gains.
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